Document 3067
 DOCN  M94A3067
 TI    Dysregulation of cytokine production as new surrogate marker in HIV-1
       infection.
 DT    9412
 AU    Tateyama M; Fukutake K; Hattori T; Ohmoto Y; Dept. of Clin. Pathol.,
       Tokyo Medical College, Japan.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):161 (abstract no. PB0069). Unique
       Identifier : AIDSLINE ICA10/94369508
 AB    OBJECTIVE: We have evaluated whether cytokine productions were improved
       after initiation of zidovudine (ZDV) or dideoxyinosine(ddI) therapy and
       correlated with clinical outcome. PATIENTS: A total of 72 HIV-1 positive
       hemophiliacs (25 patients presented with CDC stage A1, 30 with stage A2
       and 17 with C3, AIDS) were enrolled. METHODS: Cytokine productions were
       tested before and after initiation of the therapy at 6 months intervals
       for 1 year. After 100 microliters of whole blood was cultured for 24
       hours with lipopolysaccharide, IL-1 alpha and TNF-alpha levels in the
       supernatants were quantitated by ELISA methods. CD4+ cell counts and p24
       antigen were analysed simultaneously. RESULTS: Significant depressions
       of IL-1 alpha and TNF-alpha production were observed on progression of
       HIV-1 disease. Restored or deteriorated patients groups were appeared
       after starting the therapy. In asymptomatic patients (A1 and A2),
       subsequent restoration was associated with less decline of CD4+ cell
       counts. In AIDS patients (C3), the restoration reflected improved or
       stable clinical status, however, CD4+ cell counts were not associated
       with clinical outcome. Only 8 out of the 72 patients had detectable
       levels of serum p24 antigen before treatment and decline did not predict
       clinical outcome. CONCLUSION: Restoration of cytokine production in
       HIV-1 infected hemophiliacs receiving ZDV or ddI therapy reflected good
       response to treatment and slowing of disease progression. Our study
       suggested the analyses of cytokine productions were new useful markers
       of HIV infection.
 DE    Acquired Immunodeficiency Syndrome/DRUG THERAPY/IMMUNOLOGY
       Cytokines/*BLOOD  Didanosine/*THERAPEUTIC USE  Enzyme-Linked
       Immunosorbent Assay  Follow-Up Studies  Hemophilia/IMMUNOLOGY  Human
       HIV Infections/*DRUG THERAPY/IMMUNOLOGY  HIV-1/*DRUG EFFECTS/IMMUNOLOGY
       Interleukin-1/BLOOD  Leukocyte Count/DRUG EFFECTS
       Lipopolysaccharides/IMMUNOLOGY  Tumor Necrosis Factor/METABOLISM  T4
       Lymphocytes/IMMUNOLOGY  Zidovudine/*THERAPEUTIC USE  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).